Obama's stem cell policy is welcome change, but ethics are permanent feature of debate
By Jesse Reynolds,
The Jurist online
| 03. 18. 2009
President Obama's recent removal of his predecessor's stem cell policy is a welcome development. The Bush administration's restriction on the federal funding of human embryonic stem cell research was outdated and increasingly unpopular. While much of the media coverage of President Obama's announcement has focused on the research's potential and the political winners and losers, here are a few points that were overlooked:
For years, embryonic stem cell research in the US has been conducted in a federal regulatory vacuum, and the debate has been characterized by exaggerated rhetoric about imminent cures. Obama shifted the ground on both fronts. He ordered the National Institutes of Health(NIH) to draw up guidelines, which hopefully will be enforceable and apply to both publicly and privately funded research. The President also clearly called for a prohibition on reproductive cloning, which remains legal in the US and shares materials and methods with embryonic stem cell research. Furthermore, his language was optimistic but cautious; he noted that cures may not come in our lifetimes. This is a big change from advocates' over-the-top promises...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...